Griffithsin: an antiviral lectin with outstanding therapeutic potential S Lusvarghi, CA Bewley Viruses 8 (10), 296, 2016 | 143 | 2016 |
Synthesis, stereoelectronic characterization and antiparasitic activity of new 1-benzenesulfonyl-2-methyl-1, 2, 3, 4-tetrahydroquinolines RJ Pagliero, S Lusvarghi, AB Pierini, R Brun, MR Mazzieri Bioorganic & medicinal chemistry 18 (1), 142-150, 2010 | 85 | 2010 |
SARS-CoV-2 BA. 1 variant is neutralized by vaccine booster–elicited serum but evades most convalescent serum and therapeutic antibodies S Lusvarghi, SD Pollett, SN Neerukonda, W Wang, R Wang, R Vassell, ... Science Translational Medicine 14 (645), eabn8543, 2022 | 78 | 2022 |
Loop and backbone modifications of peptide nucleic acid improve g-quadruplex binding selectivity S Lusvarghi, CT Murphy, S Roy, FA Tanious, I Sacui, WD Wilson, DH Ly, ... Journal of the American Chemical Society 131 (51), 18415-18424, 2009 | 67 | 2009 |
Targeted isolation of antibodies directed against major sites of SIV Env vulnerability RD Mason, HC Welles, C Adams, BK Chakrabarti, J Gorman, T Zhou, ... PLoS Pathogens 12 (4), e1005537, 2016 | 61 | 2016 |
Avapritinib: a selective inhibitor of KIT and PDGFRα that reverses ABCB1 and ABCG2-mediated multidrug resistance in cancer cell lines CP Wu, S Lusvarghi, JC Wang, SH Hsiao, YH Huang, TH Hung, ... Molecular pharmaceutics 16 (7), 3040-3052, 2019 | 59 | 2019 |
HIV-1 gp120 as a therapeutic target: navigating a moving labyrinth P Acharya, S Lusvarghi, CA Bewley, PD Kwong Expert opinion on therapeutic targets 19 (6), 765-783, 2015 | 51 | 2015 |
SARS-CoV-2 Omicron neutralization by therapeutic antibodies, convalescent sera, and post-mRNA vaccine booster S Lusvarghi, SD Pollett, SN Neerukonda, W Wang, R Wang, R Vassell, ... BioRxiv, 2021 | 41 | 2021 |
Tivantinib, A c-met inhibitor in clinical trials, is susceptible to ABCG2-mediated drug resistance ZX Wu, Y Yang, QX Teng, JQ Wang, ZN Lei, JQ Wang, S Lusvarghi, ... Cancers 12 (1), 186, 2020 | 39 | 2020 |
The HIV-2 Rev-response element: determining secondary structure and defining folding intermediates S Lusvarghi, J Sztuba-Solinska, KJ Purzycka, GT Pauly, JW Rausch, ... Nucleic acids research 41 (13), 6637-6649, 2013 | 37 | 2013 |
The FLT3 inhibitor midostaurin selectively resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents SH Hsiao, S Lusvarghi, YH Huang, SV Ambudkar, SC Hsu, CP Wu Cancer letters 445, 34-44, 2019 | 36 | 2019 |
Sitravatinib, a Tyrosine Kinase Inhibitor, Inhibits the Transport Function of ABCG2 and Restores Sensitivity to Chemotherapy-Resistant Cancer Cells in vitro Y Yang, N Ji, QX Teng, CY Cai, JQ Wang, ZX Wu, ZN Lei, S Lusvarghi, ... Frontiers in oncology 10, 700, 2020 | 34 | 2020 |
Retrotransposon Ty1 RNA contains a 5′-terminal long-range pseudoknot required for efficient reverse transcription Q Huang, KJ Purzycka, S Lusvarghi, D Li, SFJ LeGrice, JD Boeke Rna 19 (3), 320-332, 2013 | 34 | 2013 |
Exploring Ty1 retrotransposon RNA structure within virus-like particles KJ Purzycka, M Legiewicz, E Matsuda, LD Eizentstat, S Lusvarghi, A Saha, ... Nucleic acids research 41 (1), 463-473, 2013 | 34 | 2013 |
Reversing the direction of drug transport mediated by the human multidrug transporter P-glycoprotein A Sajid, S Lusvarghi, M Murakami, EE Chufan, B Abel, MM Gottesman, ... Proceedings of the National Academy of Sciences 117 (47), 29609-29617, 2020 | 32 | 2020 |
Key substitutions in the spike protein of SARS-CoV-2 variants can predict resistance to monoclonal antibodies, but other substitutions can modify the effects S Lusvarghi, W Wang, R Herrup, SN Neerukonda, R Vassell, L Bentley, ... Journal of virology 96 (1), e01110-21, 2022 | 31 | 2022 |
Antigenic cartography of well-characterized human sera shows SARS-CoV-2 neutralization differences based on infection and vaccination history W Wang, S Lusvarghi, R Subramanian, NJ Epsi, R Wang, E Goguet, ... Cell host & microbe 30 (12), 1745-1758. e7, 2022 | 30 | 2022 |
The trispecific DARPin ensovibep inhibits diverse SARS-CoV-2 variants S Rothenberger, DL Hurdiss, M Walser, F Malvezzi, J Mayor, S Ryter, ... Nature biotechnology 40 (12), 1845-1854, 2022 | 30 | 2022 |
Multidrug transporters: recent insights from cryo-electron microscopy-derived atomic structures and animal models S Lusvarghi, RW Robey, MM Gottesman, SV Ambudkar F1000Research 9, 2020 | 29 | 2020 |
Licochalcone A selectively resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs CP Wu, S Lusvarghi, SH Hsiao, TC Liu, YQ Li, YH Huang, TH Hung, ... Journal of natural products 83 (5), 1461-1472, 2020 | 28 | 2020 |